BAY80-6946
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for BAY80-6946, covering 2018-01-08 to 2018-01-08. Get the full timeline:
Most recent: Clinical Trial Update: Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas [Phase 2]